Ivermectin and Mebendazole: Why These Repurposed Medications Are Being Studied in Cancer
Interest in repurposed medications has grown as patients, clinicians, and researchers look for affordable therapies that may influence multiple pathways involved in cancer growth, metabolism, immune function, and treatment resistance.
Ivermectin and mebendazole are two established human medications receiving attention in this area. Both have extensive histories of use for parasitic infections, known pharmacology, relatively low cost, and substantial preclinical research demonstrating potential anticancer activity.
Neither medication was originally developed for cancer. However, research suggests their biological activity may extend well beyond their antiparasitic effects.
Why Repurposing These Medications Makes Sense
Developing a new cancer drug can take many years and require enormous financial investment. Repurposing begins with medications that already have human-use histories and known pharmacologic characteristics.
Ivermectin and mebendazole are attractive research candidates because they:
Are approved for human use
Have extensive clinical-use histories
Are widely available and relatively inexpensive
Have known pharmacology and established dosing for approved conditions
Affect multiple pathways involved in cancer biology
Have demonstrated activity across numerous cancer models
May have value in combination with other therapies
Deserve further evaluation in well-designed human trials
The fact that a medication is inexpensive and generic should not make its biological effects less worthy of serious investigation.
Ivermectin’s Human Safety History
Ivermectin has been used in human medicine since the 1980s. Approximately 3.7 billion doses were distributed globally through mass-administration programs during a 30-year period.
Clinical research has generally found ivermectin to be well tolerated when appropriately prescribed. A controlled dose-escalation study found no indication of central nervous system toxicity at single doses as high as ten times the standard FDA-approved antiparasitic dose, although this does not establish the safety of prolonged high-dose cancer protocols.
This extensive human-use record provides researchers with considerably more safety and pharmacology information than would be available for an entirely new compound.
How Ivermectin May Influence Cancer Biology
Research suggests that ivermectin may influence multiple mechanisms involved in cancer development and progression, including:
WNT/β-catenin signaling
PI3K/Akt/mTOR signaling
PAK1 activity
Mitochondrial function
Oxidative stress
Apoptosis, or programmed cell death
Autophagy
Angiogenesis
Cancer stem-like cells
Drug-resistance transporters
Immune response within the tumor environment
Studies involving breast, ovarian, colorectal, and other cancer models have reported anticancer effects at laboratory concentrations described by researchers as potentially clinically feasible.
A 2026 prospective observational cohort involving ivermectin and mebendazole reported high rates of self-reported clinical benefit and generally favorable tolerability. Many participants were also using conventional treatments, supplements, and dietary changes, so the findings cannot determine which intervention produced the outcomes. However, they provide real-world observations that support the need for controlled clinical research.
A University of Florida phase 2 trial has also been registered to study ivermectin with immune-checkpoint therapy in adults with solid tumors, reflecting continued institutional interest in evaluating its potential role in oncology.
Mebendazole’s Human Safety History
Mebendazole is a human benzimidazole medication used to treat parasitic infections. Unlike fenbendazole, mebendazole is formulated and approved for human use.
It has several characteristics considered desirable in a repurposed medication, including:
A long record of human use
A generally well-characterized safety profile
Low cost
Oral administration
Known pharmacology
The ability to reach biologically relevant concentrations
Activity involving several cancer-related pathways
Published reviews describe mebendazole as a strong candidate for oncology repurposing because of its toxicity profile, accessibility, pharmacokinetics, and broad preclinical activity.
The safety of standard antiparasitic use does not automatically establish the safety of higher-dose, prolonged, or combination oncology use. Dosing, treatment duration, liver function, blood counts, and medication interactions still require individual consideration.
How Mebendazole May Influence Cancer Biology
Mebendazole appears to affect cancer through several potential mechanisms.
Microtubule Disruption
Mebendazole interferes with tubulin polymerization and microtubule formation. Microtubules are essential for cell division, making them an established target of several conventional chemotherapy drugs.
Preclinical lung-cancer research found that mebendazole caused mitotic arrest, abnormal spindle formation, and cancer-cell death through apoptosis.
Cancer Stem Cells and Treatment Resistance
Cancer stem-like cells may contribute to recurrence, metastatic spread, and resistance to treatment. Research suggests mebendazole may affect these populations and several pathways involved in treatment resistance.
Angiogenesis
Tumors need a blood supply to grow. Mebendazole has demonstrated anti-angiogenic activity in preclinical research, meaning it may interfere with signals involved in the development of tumor-supporting blood vessels.
Apoptosis and Cancer-Cell Growth
Studies involving lung, breast, colon, ovarian, brain, and other cancer models have reported inhibition of cancer-cell growth and induction of programmed cell death.
Potential Treatment Synergy
Preclinical studies suggest that mebendazole may work synergistically with certain chemotherapy agents and radiation. This does not establish the safety of every combination, but it supports research into mebendazole as a possible adjunct rather than viewing it only as a replacement for other care.
What Makes the Evidence Significant?
The evidence is not limited to a single laboratory experiment.
Across the published literature, researchers have reported:
Activity in multiple cancer-cell lines
Anticancer effects in animal models
Effects on multiple cancer-related pathways
Potential activity against cancer stem-like cells
Possible synergy with chemotherapy and radiation
Established human-use histories for both medications
Early human and observational data
Continued interest in clinical investigation
A 2026 review of antiparasitic medications in oncology described compelling anticancer properties across a broad range of preclinical models while recognizing the need for adequately powered clinical trials.
It is accurate to describe the evidence as substantial and promising. It is also important to distinguish this from definitive proof of improved survival or tumor control in randomized human trials.
Both statements can be true.
Why Monitoring Still Matters
A favorable safety history does not mean that every dose, duration, combination, or patient situation carries the same risk.
Important considerations may include:
Liver and kidney function
Current chemotherapy, immunotherapy, or targeted therapy
Other prescription medications
Supplement use
Potential CYP enzyme or drug-transporter interactions
Neurologic history
Blood counts
Gastrointestinal tolerance
Duration and cumulative exposure
Monitoring is not evidence that a medication is inherently dangerous. It is part of responsible individualized care—particularly when medications are used outside their approved indications or combined with other therapies.
Patients Deserve Access to the Full Conversation
People navigating cancer should not be mocked or dismissed for asking about ivermectin, mebendazole, or other repurposed medications.
They deserve an honest discussion that includes:
The strength of the mechanistic and preclinical evidence
Existing human-use and safety information
Emerging observational or clinical data
What remains unknown
Cancer-specific relevance
Potential interactions
Appropriate monitoring
The person’s goals and available options
There is a meaningful difference between making an unsupported promise and acknowledging a therapy’s legitimate scientific potential.
The Bottom Line
Ivermectin and mebendazole are established human medications with extensive clinical-use histories and substantial bodies of preclinical anticancer research.
Their proposed activity is biologically plausible, multi-targeted, and supported across numerous laboratory and animal models. Early human observations and active clinical interest strengthen the argument that these medications deserve serious, well-funded investigation.
They should not be marketed as guaranteed cures. They also should not be dismissed as having “no evidence.”
Patients deserve accurate information, appropriate monitoring, respectful collaboration, and the freedom to make informed decisions about the options they wish to explore.
Need Help Understanding the Research?
RootedWellness provides individualized education and advocacy for people interested in metabolic, integrative, repurposed, and emerging approaches.
Support may include research review, interaction considerations, laboratory-monitoring questions, preparation for medical appointments, and coordination with independent licensed clinicians when appropriate.
[Schedule a Cancer Support Strategy Session]
